From Clinical to Commercial: How to Build a Scalable Digital Foundation in CGT Manufacturing

Access the video by filling out the form.

Key Takeaways

  • Learn practical, stage-appropriate steps to improve process efficiency, from early clinical runs to global commercial supply.
  • See how digital systems can work in concert to harmonize data, streamline QA/QC, and enable faster tech transfer.
  • Review real-world metrics from leading cell therapy manufacturers, including how one pioneer achieved a 50% reduction in review times while maintaining 99% right-first-time manufacturing.
  • Discover how regulatory expectations impact manufacturing comparability, release testing, and validated state management.

Gain strategies for sustainable growth that balance hardware investments with a scalable digital foundation to deliver therapies faster and more reliably.

About This Event

In advanced therapy manufacturing, every minute matters. Cell and gene therapies are patient-specific or highly specialized, and delays anywhere in the process can impact both regulatory timelines and patient outcomes. Yet as programs scale from early clinical runs to global commercial supply, manufacturers often discover that bottlenecks aren't just about bioreactors and clean rooms – they're hidden in documentation, quality control, tech transfer, and training. The ability to standardize processes becomes the linchpin for operational efficiency.

This webinar will explore four operational challenges that can lead to bottlenecks, compliance issues, and delivery delays:

  • Comparability and multi-site tech transfer.
  • End-to-end operations.
  • Workforce enablement and knowledge capture.
  • Asset reliability & validated state.

Drawing on recent regulatory updates, industry benchmarks, and case examples, we'll outline practical, scalable steps manufacturers can take – whether you're running your first clinical batches or operating at full commercial scale.

Key Takeaways

  • Learn practical, stage-appropriate steps to improve process efficiency, from early clinical runs to global commercial supply.
  • See how digital systems can work in concert to harmonize data, streamline QA/QC, and enable faster tech transfer.
  • Review real-world metrics from leading cell therapy manufacturers, including how one pioneer achieved a 50% reduction in review times while maintaining 99% right-first-time manufacturing.
  • Discover how regulatory expectations impact manufacturing comparability, release testing, and validated state management.

Gain strategies for sustainable growth that balance hardware investments with a scalable digital foundation to deliver therapies faster and more reliably.

Caitlin Minton-Smith

Senior Product Marketing Manager

MasterControl

Caitlin Minton-Smith has over 15 years of experience in the life sciences industry and extensive expertise in online, print, and visual media communication. In her current role as senior product marketing manager, she is responsible for creating go-to-market strategies, developing product positioning, crafting messaging, and executing strategic marketing campaigns and has been directly involved in the launch of several MasterControl products. Minton-Smith brings comprehensive product, market, and customer knowledge to deliver innovative solutions to deeply rooted problems and strives to empower cross-functional teams to maximize success.

Adrienne Mendoza

Chief Operating Officer

BBG Advanced Therapies

Adrienne Mendoza is the Chief Operating Officer of BBG Advanced Therapies, a mission-driven, nonprofit organization working to redefine how patients access life-saving cell and gene therapies. She is leading efforts to challenge outdated models and remove the barriers that limit access to these treatments. With a background spanning pharmaceutical operations, advanced therapies, quality and regulatory systems, healthcare administration, and systemic change, Adrienne is reshaping how the industry thinks about scalability, infrastructure, and equitable access. Her goal is simple but urgent: dismantle logistical barriers and bring cell and gene therapies within reach for more patients, regardless of geography. 
[ { "key": "fid#1", "value": ["Everything else"] } ]